Vexdo 20/Vexdo 80 Dosage/Direction for Use

Breast Cancer (BC): Docetaxel is given by intravenous infusion in glucose 5% or sodium chloride 0.9% at a concentration not exceeding 0.74 mg/mL. Infusion is normally over 1 hour. Premedication with an oral corticosteroid, such as dexamethasone 16 mg daily, for 3 days starting 1 day before docetaxel is recommended with many regimens. The licensed dose for docetaxel as a single agent in the treatment of breast cancer after failure of previous chemotherapy is 60 to 100 mg/m² once every 3 weeks. A dose of 75 mg/m² once every 3 weeks is given in combination therapy with doxorubicin, or capecitabine, or when used as adjuvant therapy with doxorubicin and cyclophosphamide. When used with trastuzumab, docetaxel is given at a dose of 100 mg/m² once every 3 weeks.
Non-Small Cell Lung Cancer (NSCLC): The dose for non-small cell lung cancer is 75 mg/m² once every 3 weeks, for both first-line combination therapy and monotherapy after failure of previous chemotherapy.
Gastro Adenocarcinoma (GC): For gastric adenocarcinoma docetaxel 75 mg/m² is given before cisplatin and fluorouracil; treatment is repeated every 3 weeks.
Squamous Cell Carcinomas of the Head and Neck Cancer (SCCHN): In the induction treatment of head and neck cancer, the recommended dose of docetaxel is 75 mg/m², given before cisplatin and fluorouracil; treatment is given every 3 weeks for 3 cycles, followed by chemoradiotherapy, or for 4 cycles when followed by radiotherapy alone.
Hormone Refractory Prostate Cancer (HRPC): For prostate cancer, the dose of docetaxel is 75 mg/m² once every 3 weeks, with prednisone or prednisolone 5 mg orally twice daily given continuously.
The use of prednisone or prednisolone reduces the need for a premedication corticosteroid; dexamethasone 8 mg may be given at 12 hours, 3 hours, and 1 hour before docetaxel. Regular blood counts are required, and dosage in subsequent courses should be reduced in patients who experience severe or febrile neutropenia, or severe cutaneous reactions or peripheral neuropathy. The dose of docetaxel should be reduced in hepatic impairment.
Administration: Docetaxel has been investigated as a low dose weekly infusion, in patient groups such as the elderly, those with poor performance status, or refractory disease. Weekly doses of 30 to 40 mg/m² are considered to be of similar efficacy to the standard three-weekly dosage regimen. A pharmacokinetic study in 20 elderly patients suggested that a suitable starting dose might be 26 mg/m², increased provided there was no toxicity.
Administration in hepatic impairment: The doses of docetaxel monotherapy should be reduced from 100 mg/m² to 75 mg/m² in mild to moderate hepatic impairment, defined as alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) more than 1.5 times the upper limit of normal (ULN), and alkaline phosphatase more than 2.5 times the ULN. Hepatic function should be monitored; use should be avoided if possible in severe hepatic impairment. The use of docetaxel in patients with bilirubin above ULN, or in those with mild to moderate hepatic impairment.